March 24, 2020 / 1:24 PM / 10 days ago

BRIEF-Rafael Pharmaceuticals Enrolls More Than 75% Of Patients Needed For Pivotal Phase 3 TrialOf CPI-613 For Patients With Metastatic Pancreatic Cancer

March 24 (Reuters) - Rafael Holdings Inc:

* RAFAEL PHARMACEUTICALS ENROLLS MORE THAN 75% OF PATIENTS NEEDED FOR PIVOTAL PHASE 3 TRIAL (AVENGER 500) OF CPI-613®️ (DEVIMISTAT) FOR PATIENTS WITH METASTATIC PANCREATIC CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below